.Monopar Therapeutics is bouncing back a medication coming from the dump of AstraZeneca’s uncommon disease pipe. It has accredited ALXN-1840, a prospect for the therapy
Read moreAZ describes AI-enabled TROP2 biomarker method for Daiichi ADC
.AstraZeneca has used artificial intelligence to create an unique biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), hoping to differentiate the antibody-drug conjugate (ADC)
Read moreAN 2 halves roll call, ceases period 3 test after data let down
.AN2 Therapeutics is actually reconsidering its own business in reaction to lackluster midphase data, promising to give up half its own employees and also cease
Read moreALX’s waning CD47 reaction fee delivers supply spiraling down
.ALX Oncology’s phase 2 gastric cancer cells action rate has damaged. After finding its CD47 blocker simply hammered command over the first one-half of the
Read moreAC Immune views ‘site’ prospective in Alzheimer’s drug records
.After greater than two decades of focus on neurodegenerative ailments, Swiss biotech a/c Immune system claims it could possess a video game changer on its
Read more